NDAIRRIGATIONSOLUTIONPriority Review
Approved
Oct 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
RENACIDIN (citric acid, gluconolactone and magnesium carbonate) by United Therapeutics is acidifying activity [moa]. First approved in 1990.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENACIDIN is a urological irrigation solution containing citric acid, gluconolactone, and magnesium carbonate that works through acidifying activity to dissolve kidney and bladder calculi. It is administered directly via irrigation to affected urinary structures. This niche specialty product addresses a specific surgical/urological need with limited but established clinical use.
$0.003BPart D
LOE ApproachingStable
This legacy specialty product has limited commercial scale with ~13,800 annual claims; the approaching loss of exclusivity signals a contraction phase requiring cost-conscious portfolio management.
Mechanism of Action
Acidifying Activity
Pharmacologic Class:
Calculi Dissolution Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENACIDIN offers a specialized niche career opportunity in legacy product management within a declining-revenue lifecycle phase. This role rewards operational excellence, relationship management with urology centers, and formulary/reimbursement defense over innovation-driven growth.
Brand ManagerProduct Manager
Worked on RENACIDIN at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.